How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Panel of peripheral biomarkers for the early diagnosis of Parkinson's disease

Organization name

Enterprise Europe Network

Profile

Description

The research group found out that the levels of 20 proteins in peripheral blood are significantly different in Parkinson's disease patients with respect to control subjects. These results have been obtained through an unbiased proteomics biomarkers discovery. A predictive function may be calculated as a linear combination of the measured levels in order to classify affected subjects and to assign a progression score. Each of the enrolled subjects has been iteratively excluded from the cohort and independently classified. In this way, sensitivity = 100% and specificity = 94% were calculated.

The research group is looking for partners in order to jointly develop a clinical assay for the early, preclinical diagnosis of Parkinson's disease based on the measurement of peripheral blood proteins. The group is interested in a licence agreement as well.

Innovations and advantages of the offer

Diagnosis of Parkinson's disease is currently based on the clinical evaluation of extrapyramidal signs, such as tremor, rigidity and bradykinesia, when the degeneration of dopaminergic nigral neurons has raised over 70%. The identification of specific biomarkers is critical for the early diagnosis of the disease and also to monitor its progression. Additionally, the assessment of disease-modifying drugs requires the identification of early-stage patients to be included in clinical studies. Non-motor signs frequently precede the onset of PD but they may be unspecific, whereas instrumental investigations are characterized by high cost and use of radioactive tracers that hamper their application population-wide. Molecular biomarkers in body fluids are likely to meet the expectation of unprecedented specificity, in particular when a panel of biomarkers is concerned, together with costs that are lower than those of imaging/functional biomarkers.

Current and Potential Domain of Application

  • The invention finds application in the field of diagnostic test products and equipment

List of Keywords

Technology

  • Diagnostics, Diagnosis
  • Neurology, Brain Research
  • In vitro Testing, Trials
  • Gene Expression, Proteom Research

Market

  • Diagnostic
  • Diagnostic test products and equipment

Current Stage of Development

  • Development phase - Laboratory tested

Exploitation of RTD Results

  • EU RTD results (FP4 to FP7)

Collaboration Type

  • License Agreement
  • Joint further development
  • Testing of new applications

Comments

  • Type of partner sought: commercial
  • Specific area of activity of the partner: diagnostics, quantitative proteomics instruments
  • Task to be performed by the partner sought: high-throughput validation of the diagnostic assay or purchasing the licence

Ref: 12 IT 54W2 3R14

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries